What is aTyr Pharma, Inc.'s earnings per share (EPS)?

aTyr Pharma, Inc. (ATYR) reported diluted earnings per share of -$0.80 for fiscal year 2025. This represents a 7.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

aTyr Pharma, Inc. (ATYR) Financials

ATYR

FY2025 annual

Revenue $190K -19.1% YoY

Net Income -$74.1M -15.8% YoY

EPS (Diluted) -$0.80 +7.0% YoY

Free Cash Flow -$62.1M +10.3% YoY

Market Cap $21.1M as of Oct 12, 2026

Price / Sales 111x on $190K revenue, FY2025

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 0.4x on $48.8M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 12, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 7, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 7, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ATYR SEC filings page.

aTyr Pharma, Inc. (ATYR) reported $190K in revenue for fiscal year 2025, down 19.1% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ATYR FY2025 2026-10-04

aTyr operates as a development-stage biotech: research spending vastly exceeds revenue, while financing supplies capital for continued operations.

Cash conversion is unusually transparent: FY2025 operating cash flow of -$62.0M nearly matched free cash flow of -$62.1M, because capital expenditures were only $77K. That narrow gap indicates the reported cash requirement is driven mainly by ongoing research and administration, not heavy physical investment.

R&D intensity defines the business: FY2025 research spending reached $60.2M against just $190K of revenue, so current financial results measure development funding far more than commercial operating scale. Net loss widened to $74.1M as operating expenses continued to dominate the income statement.

External financing remains central: FY2025 financing cash inflow of $66.0M was broadly comparable to the $62.0M operating cash outflow, while shares outstanding increased from 88.9M to 98.1M. The balance sheet remains less debt-dependent, with debt-to-equity at 0.4x and a current ratio of 5.3x; reported liquidity equaled 15.2 months of the latest annual outflow.

Financial Health Signals

Financial health score not available

aTyr Pharma, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-10.54

aTyr Pharma, Inc. scores -10.54, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($21.1M) relative to total liabilities ($25.5M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

1/7

aTyr Pharma, Inc. passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality No Cash Backing

N/A

aTyr Pharma, Inc. reported a net loss of $74.1M while operations used $62.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$10.7M

YoY+46.8%

QoQ+5.0%

aTyr Pharma, Inc.'s EBITDA was -$10.7M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 46.8% from the same quarter a year earlier. Against the prior quarter it is up 5.0%.

Net Income

-$10.3M

YoY+47.2%

QoQ+4.5%

aTyr Pharma, Inc. reported -$10.3M in net income in Q2 2026. This represents an increase of 47.2% from the same quarter a year earlier. Against the prior quarter it is up 4.5%.

EPS (Diluted)

-$0.11

YoY+50.0%

QoQ0.0%

aTyr Pharma, Inc. earned -$0.11 per diluted share (EPS) in Q2 2026. This represents an increase of 50.0% from the same quarter a year earlier. It is unchanged from the prior quarter.

Revenue

Not reported for Q2 2026.

Cash & Balance Sheet

Free Cash Flow

-$9.4M

YoY+32.2%

QoQ+25.5%

aTyr Pharma, Inc. recorded an outflow of $9.4M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents an increase of 32.2% from the same quarter a year earlier. Against the prior quarter it is up 25.5%.

Cash & Debt

$16.2M

YoY-6.2%

QoQ+61.5%

5Y CAGR+49.1%

10Y CAGR-9.4%

aTyr Pharma, Inc. held $16.2M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

98M

YoY+0.1%

QoQ0.0%

5Y CAGR+42.1%

10Y CAGR+15.3%

aTyr Pharma, Inc. had 98M shares outstanding in Q2 2026. This represents an increase of 0.1% from the same quarter a year earlier. It is unchanged from the prior quarter.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-21.1%

YoY+5.0pp

QoQ-2.5pp

aTyr Pharma, Inc.'s ROE was -21.1% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 5.0 percentage points from the same quarter a year earlier. Against the prior quarter it is down 2.5 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$6.7M

YoY-56.1%

QoQ-7.8%

aTyr Pharma, Inc. invested $6.7M in research and development in Q2 2026. This represents a decrease of 56.1% from the same quarter a year earlier. Against the prior quarter it is down 7.8%.

Capital Expenditures

$73K

YoY+711.1%

QoQ-47.1%

5Y CAGR-5.3%

10Y CAGR-8.4%

aTyr Pharma, Inc. invested $73K in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 711.1% from the same quarter a year earlier. Against the prior quarter it is down 47.1%.

Share Buybacks

Not reported for Q2 2026.

ATYR Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ATYR quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Revenue	N/A	$190K-19.1%	$235K-33.4%	$353K-96.6%	$10.4M	$0-100.0%	$10.5M+2377.5%	$422K	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$60.2M+10.8%	$54.4M+28.6%	$42.3M-1.2%	$42.8M+84.0%	$23.3M+34.5%	$17.3M+23.1%	$14.0M-31.1%	$20.4M-32.2%	$30.1M-29.8%	$42.8M+24.2%	$34.5M+105.7%	$16.8M+21.3%	$13.8M
SG&A Expenses	N/A	$17.6M+27.7%	$13.8M+6.1%	$13.0M-7.2%	$14.0M+30.1%	$10.8M+18.5%	$9.1M-3.0%	$9.4M-24.8%	$12.4M-27.2%	$17.1M+13.1%	$15.1M+15.1%	$13.1M+93.5%	$6.8M+18.7%	$5.7M
Operating Income	N/A	-$77.6M-14.3%	-$67.9M-23.7%	-$54.9M-18.3%	-$46.4M-36.4%	-$34.0M-113.8%	-$15.9M+30.8%	-$23.0M+30.0%	-$32.8M+30.4%	-$47.1M+18.6%	-$57.9M-21.7%	-$47.6M-102.2%	-$23.6M-20.5%	-$19.5M
EBITDA	N/A	-$77.0M-14.5%	-$67.2M-23.7%	-$54.3M-17.7%	-$46.2M-37.7%	-$33.5M-118.6%	-$15.3M+31.3%	-$22.3M+30.3%	-$32.1M+30.9%	-$46.4M+18.6%	-$57.0M-22.0%	-$46.7M-105.7%	-$22.7M-20.7%	-$18.8M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$386K-53.6%	$832K+87.4%	$444K
Income Tax	N/A	$0	$0	$0	$0	$0	$0	$0	$0	N/A	-$49K	N/A	N/A	N/A
Net Income	N/A	-$74.1M-15.8%	-$64.0M-27.1%	-$50.4M-11.1%	-$45.3M-34.3%	-$33.8M-108.1%	-$16.2M0.0%	-$16.2M+53.0%	-$34.5M+28.4%	-$48.2M+16.7%	-$57.9M-20.6%	-$48.0M-97.0%	-$24.4M-21.7%	-$20.0M
EPS (Basic)	N/A	-$0.80+7.0%	-$0.86+8.5%	-$0.94+41.3%	-$1.60+9.6%	-$1.770.0%	-$1.77	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	-$0.62	-$0.80+7.0%	-$0.86+8.5%	-$0.94	-$1.60	-$1.77	-$1.77	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	93M+25.2%	74M+38.5%	54M	28M	19M	9M	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	N/A	N/A	N/A	$190K	$0	$0-100.0%	N/A	$0-100.0%
R&D Expenses	$6.7M-56.1%	$7.3M-38.1%	N/A	$22.1M+49.5%	$15.4M+10.1%	$11.8M-11.6%	N/A	$14.8M+43.5%
SG&A Expenses	$4.1M-16.1%	$4.1M+4.0%	N/A	$4.8M+44.0%	$4.9M+47.5%	$4.0M+12.9%	N/A	$3.3M+25.9%
Operating Income	-$10.9M+46.4%	-$11.4M+27.5%	N/A	-$26.7M-47.4%	-$20.3M-17.3%	-$15.8M+5.2%	N/A	-$18.1M-43.8%
EBITDA	-$10.7M+46.8%	-$11.3M+27.8%	N/A	-$26.6M-48.0%	-$20.1M-17.6%	-$15.6M+5.2%	N/A	-$18.0M-44.4%
Net Income	-$10.3M+47.2%	-$10.8M+27.5%	N/A	-$25.7M-49.2%	-$19.5M-19.8%	-$14.9M+3.9%	N/A	-$17.3M-52.2%
EPS (Basic)	-$0.11+50.0%	-$0.11+35.3%	-$0.14+17.6%	-$0.26-13.0%	-$0.22+4.3%	-$0.17+26.1%	-$0.17+32.0%	-$0.23-15.0%
EPS (Diluted)	-$0.11+50.0%	-$0.11+35.3%	-$0.14+17.6%	-$0.26-13.0%	-$0.22+4.3%	-$0.17+26.1%	-$0.17+32.0%	-$0.23-15.0%
Diluted Shares (Avg)	98M+8.8%	98M+13.4%	N/A	97M+28.2%	90M+24.7%	86M+30.9%	N/A	76M+31.0%

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense, Income Tax.

ATYR Balance Sheet

ATYR quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Total Assets	$93.0M-4.0%	$96.8M-19.7%	$120.7M+26.0%	$95.8M-17.1%	$115.5M+198.3%	$38.7M+7.0%	$36.2M-31.4%	$52.7M-41.0%	$89.4M+11.0%	$80.5M-37.9%	$129.7M+528.1%	$20.6M	N/A
Current Assets	$80.2M-2.1%	$82.0M-20.4%	$103.0M+27.4%	$80.9M-28.8%	$113.6M+219.6%	$35.5M+11.3%	$31.9M-37.2%	$50.8M-41.6%	$87.0M+16.3%	$74.8M-23.7%	$98.0M+493.3%	$16.5M	N/A
Cash & Equivalents	$10.7M-2.8%	$11.1M-51.0%	$22.5M+125.9%	$10.0M+327.3%	$2.3M-86.2%	$17.0M+84.1%	$9.2M-59.9%	$23.0M+8.9%	$21.1M-45.1%	$38.4M-27.6%	$53.0M+281.5%	$13.9M-61.9%	$36.5M
Short-Term Investments	$67.9M+11.3%	$61.1M-19.2%	$75.6M+34.6%	$56.2M-46.8%	$105.6M+616.4%	$14.7M-32.8%	$21.9M-17.5%	$26.6M-58.5%	$64.0M+89.7%	$33.8M-20.6%	$42.5M+2075.5%	$2.0M	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0-100.0%	$4.0M-86.6%	$29.8M	$0	$0
Total Liabilities	$25.5M-4.8%	$26.8M-10.6%	$30.0M+23.3%	$24.3M+290.0%	$6.2M-11.9%	$7.1M-52.8%	$15.0M-21.4%	$19.1M-24.0%	$25.1M+41.7%	$17.7M+21.2%	$14.6M-86.9%	$111.7M	N/A
Current Liabilities	$15.1M+1.2%	$15.0M-8.8%	$16.4M+18.4%	$13.9M+130.5%	$6.0M+2.5%	$5.9M-54.6%	$12.9M+19.3%	$10.8M+4.3%	$10.4M+21.9%	$8.5M-29.8%	$12.1M+20.1%	$10.1M	N/A
Non-Current Liabilities	$10.4M-12.4%	$11.8M-12.8%	$13.6M+29.8%	$10.5M+4590.6%	$223K-81.6%	$1.2M-41.7%	$2.1M-74.8%	$8.3M-43.9%	$14.7M+60.0%	$9.2M+271.3%	$2.5M-97.6%	$101.5M	N/A
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$8.3M-43.9%	$14.7M+60.0%	$9.2M+417.9%	$1.8M	N/A	N/A
Total Equity	$67.5M-3.6%	$70.0M-22.8%	$90.7M+26.9%	$71.5M-34.6%	$109.3M+245.3%	$31.6M+49.4%	$21.2M-37.0%	$33.6M-47.6%	$64.2M+2.3%	$62.8M-45.4%	$115.0M+226.4%	-$91.0M-37.7%	-$66.1M
Retained Earnings	-$606.2M-13.9%	-$532.0M-13.7%	-$468.0M-12.1%	-$417.6M-12.2%	-$372.3M-10.0%	-$338.5M-5.0%	-$322.3M-7.9%	-$298.7M-13.1%	-$264.2M-22.3%	-$216.0M-36.6%	-$158.1M-43.6%	-$110.2M	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$69.8M-31.2%	$79.7M-18.1%	$93.0M-4.0%	$106.7M+16.4%	$101.5M-4.2%	$97.2M-14.1%	$96.8M-19.7%	$91.6M-26.7%
Current Assets	$58.4M-33.3%	$67.6M-18.8%	$80.2M-2.1%	$93.0M+21.9%	$87.5M-3.1%	$83.3M-14.1%	$82.0M-20.4%	$76.3M-28.9%
Cash & Equivalents	$16.2M-6.2%	$10.0M-3.4%	$10.7M-2.8%	$6.2M-46.3%	$17.2M+153.0%	$10.4M+52.2%	$11.1M-51.0%	$11.5M+17.1%
Short-Term Investments	$41.3M-34.6%	$56.5M-14.4%	$67.9M+11.3%	$79.0M+44.9%	$63.1M-11.9%	$66.0M-15.1%	$61.1M-19.2%	$54.5M-41.0%
Long-Term Investments	$0	$0	$0	$5.1M	$0	$0	$0	$0
Total Liabilities	$21.0M-21.2%	$21.7M-2.1%	$25.5M-4.8%	$26.4M+0.5%	$26.7M+9.7%	$22.2M-22.9%	$26.8M-10.6%	$26.3M-1.5%
Current Liabilities	$11.4M-26.6%	$11.7M+9.5%	$15.1M+1.2%	$15.7M+11.0%	$15.5M+31.2%	$10.7M-33.1%	$15.0M-8.8%	$14.1M+9.6%
Non-Current Liabilities	$9.6M-13.6%	$10.0M-13.0%	$10.4M-12.4%	$10.7M-11.8%	$11.2M-10.7%	$11.5M-10.1%	$11.8M-12.8%	$12.2M-11.8%
Total Equity	$48.8M-34.8%	$57.9M-22.8%	$67.5M-3.6%	$80.2M+22.8%	$74.8M-8.3%	$75.0M-11.1%	$70.0M-22.8%	$65.3M-33.6%
Retained Earnings	-$627.3M-10.7%	-$617.0M-12.8%	-$606.2M-13.9%	-$592.2M-14.5%	-$566.5M-13.3%	-$546.9M-13.1%	-$532.0M-13.7%	-$517.1M-14.1%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

ATYR Cash Flow Statement

ATYR quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Operating Cash Flow	-$54.5M	-$62.0M+10.3%	-$69.1M-108.1%	-$33.2M+20.7%	-$41.9M-26.6%	-$33.1M-116.2%	-$15.3M+23.5%	-$20.0M+35.6%	-$31.1M+26.7%	-$42.4M+19.9%	-$52.9M-43.7%	-$36.8M-61.2%	-$22.8M-31.8%	-$17.3M
Depreciation & Amortization	N/A	$664K-6.2%	$708K+19.6%	$592K+155.2%	$232K-51.2%	$475K-16.5%	$569K-10.4%	$635K-14.9%	$746K+4.6%	$713K-20.8%	$900K+3.6%	$869K+4.8%	$829K+16.1%	$714K
Stock-Based Compensation	N/A	$5.0M+67.2%	$3.0M+15.0%	$2.6M+20.7%	$2.2M+33.5%	$1.6M+10.2%	$1.5M-17.8%	$1.8M-48.0%	$3.4M-49.4%	$6.8M+34.9%	$5.0M+3.6%	$4.9M+171.1%	$1.8M+1055.5%	$155K
Capital Expenditures	$279K	$77K+18.5%	$65K-98.5%	$4.2M+156.9%	$1.6M+754.7%	$192K-5.0%	$202K+155.7%	$79K-86.7%	$594K-54.7%	$1.3M+118.7%	$600K-9.6%	$664K+166.7%	$249K-61.3%	$644K
Free Cash Flow	-$54.8M	-$62.1M+10.3%	-$69.2M-84.8%	-$37.4M+14.0%	-$43.5M-30.8%	-$33.3M-114.6%	-$15.5M+22.8%	-$20.1M+36.5%	-$31.7M+27.5%	-$43.7M+18.3%	-$53.5M-42.7%	-$37.5M-62.4%	-$23.1M-28.5%	-$18.0M
Investing Cash Flow	$22.9M	-$5.1M-129.3%	$17.2M+185.6%	-$20.1M-142.6%	$47.2M+151.6%	-$91.6M-1427.0%	$6.9M+40.1%	$4.9M-86.8%	$37.2M+234.5%	-$27.6M-182.4%	$33.5M	N/A	N/A	N/A
Financing Cash Flow	$29.2M	$66.0M+65.6%	$39.9M-39.8%	$66.2M+1115.0%	$5.5M-95.0%	$110.0M+581.6%	$16.1M+1108.3%	$1.3M+131.5%	-$4.2M-108.0%	$52.7M+1022.1%	$4.7M	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$9.4M+32.7%	-$12.5M+18.8%	-$12.2M+7.1%	-$20.5M-55.6%	-$13.9M+32.1%	-$15.4M+31.1%	-$13.1M-18.7%	-$13.2M-37.7%
Depreciation & Amortization	$168K+1.2%	$162K-3.0%	$166K-5.1%	$165K-7.3%	$166K-6.2%	$167K-6.2%	$175K0.0%	$178K+1.1%
Stock-Based Compensation	$1.1M-12.3%	$1.3M+11.0%	N/A	$1.3M+73.8%	$1.3M+79.5%	$1.2M+59.2%	N/A	$752K+13.3%
Capital Expenditures	$73K+711.1%	$138K	$31K+24.0%	$37K+146.7%	$9K+12.5%	$0-100.0%	$25K+47.1%	$15K-97.3%
Free Cash Flow	-$9.4M+32.2%	-$12.7M+17.9%	-$12.2M+7.1%	-$20.5M-55.7%	-$13.9M+32.0%	-$15.4M+31.2%	-$13.2M-18.8%	-$13.2M-30.2%
Investing Cash Flow	$15.3M+364.2%	$11.5M+360.0%	$16.4M+370.2%	-$20.4M-213.5%	$3.3M-50.9%	-$4.4M-226.0%	-$6.1M-134.2%	$17.9M+309.4%
Financing Cash Flow	-$129K-100.7%	-$142K-100.8%	-$131K-100.7%	$29.6M+28306.7%	$17.9M+33.6%	$18.6M+141.0%	$18.8M+212.2%	-$105K-103.9%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

ATYR Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ATYR quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Operating Margin	-40856.3%	-28899.6%	-15557.8%	-446.8%	N/A	-152.2%	-5445.0%	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	-39009.5%	-27243.8%	-14274.5%	-436.5%	N/A	-155.2%	-3844.6%	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-109.8%-18.4pp	-91.4%-35.9pp	-55.6%+7.9pp	-63.4%-32.5pp	-30.9%+20.4pp	-51.3%+25.3pp	-76.6%+26.0pp	-102.6%-27.5pp	-75.0%+17.1pp	-92.1%-50.4pp	-41.7%	N/A	N/A
Return on Assets	-79.7%-13.6pp	-66.1%-24.4pp	-41.8%+5.6pp	-47.3%-18.1pp	-29.2%+12.7pp	-41.9%+2.9pp	-44.8%+20.6pp	-65.4%-11.5pp	-53.9%+17.9pp	-71.9%-34.9pp	-37.0%+81.0pp	-118.0%	N/A
Current Ratio	5.30-0.2x	5.48-0.8x	6.27+0.4x	5.83-13.1x	18.89+12.8x	6.06+3.6x	2.47-2.2x	4.69-3.7x	8.37-0.4x	8.77+0.7x	8.06+6.4x	1.63	N/A
Debt-to-Equity	0.380.0x	0.38+0.1x	0.330.0x	0.34+0.3x	0.06-0.2x	0.22-0.5x	0.71+0.5x	0.250.0x	0.23+0.1x	0.15+0.1x	0.02	N/A	N/A
Asset Turnover	0.000.0x	0.000.0x	0.00-0.1x	0.11+0.1x	0.00-0.3x	0.27+0.3x	0.01	N/A	N/A	N/A	N/A	N/A	N/A
FCF Margin	-32664.7%	-29440.0%	-10605.1%	-419.1%	N/A	-148.3%	-4761.1%	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Margin	N/A	N/A	N/A	-14076.3%	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	-13549.5%	N/A	N/A	N/A	N/A
Return on Equity	-21.1%+5.0pp	-18.6%+1.2pp	N/A	-32.1%-5.7pp	-26.1%-6.1pp	-19.8%-1.5pp	N/A	-26.4%-14.9pp
Return on Assets	-14.8%+4.5pp	-13.6%+1.7pp	N/A	-24.1%-5.3pp	-19.2%-3.8pp	-15.3%-1.6pp	N/A	-18.8%-9.8pp
Current Ratio	5.12-0.5x	5.78-2.0x	5.30-0.2x	5.93+0.5x	5.63-2.0x	7.79+1.7x	5.48-0.8x	5.41-2.9x
Debt-to-Equity	0.43+0.1x	0.37+0.1x	0.380.0x	0.33-0.1x	0.36+0.1x	0.300.0x	0.38+0.1x	0.40+0.1x
Asset Turnover	N/A	N/A	N/A	0.000.0x	0.000.0x	0.000.0x	N/A	0.000.0x
FCF Margin	N/A	N/A	N/A	-10796.3%	N/A	N/A	N/A	N/A

Not reported in any period shown, so not listed: Gross Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
aTyr Pharma, Inc. ATYR	FY2025	$190K	-$74.1M	N/A	$21.1M	—
Opthea Limited American OPT	FY2025	$25K	-$162.8M	N/A	$524.8M	—
Kodiak Sciences Inc KOD	FY2025	N/A	-$230.0M	N/A	$6.3B	—
Oruka Therapeutics, Inc. ORKA	FY2025	N/A	-$105.4M	N/A	$5.4B	—
Olema Pharmaceuticals, Inc. OLMA	FY2025	N/A	-$162.5M	N/A	$684.2M	—

Where aTyr Pharma, Inc. Ranks

Frequently Asked Questions

What is aTyr Pharma, Inc.'s annual revenue?

aTyr Pharma, Inc. (ATYR) reported $190K in total revenue for fiscal year 2025. This represents a -19.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is aTyr Pharma, Inc.'s revenue growing?

aTyr Pharma, Inc. (ATYR) revenue declined by 19.1% year-over-year, from $235K to $190K in fiscal year 2025.

Is aTyr Pharma, Inc. profitable?

No, aTyr Pharma, Inc. (ATYR) reported a net income of -$74.1M in fiscal year 2025.

What is aTyr Pharma, Inc.'s EBITDA?

aTyr Pharma, Inc. (ATYR) had EBITDA of -$77.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is aTyr Pharma, Inc.'s return on equity (ROE)?

aTyr Pharma, Inc. (ATYR) has a return on equity of -109.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is aTyr Pharma, Inc.'s free cash flow?

aTyr Pharma, Inc. (ATYR) recorded an outflow of $62.1M in free cash flow during fiscal year 2025. This represents a 10.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is aTyr Pharma, Inc.'s operating cash flow?

aTyr Pharma, Inc. (ATYR) recorded an outflow of $62.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are aTyr Pharma, Inc.'s total assets?

aTyr Pharma, Inc. (ATYR) had $93.0M in total assets as of fiscal year 2025, including both current and long-term assets.

What are aTyr Pharma, Inc.'s capital expenditures?

aTyr Pharma, Inc. (ATYR) invested $77K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does aTyr Pharma, Inc. spend on research and development?

aTyr Pharma, Inc. (ATYR) invested $60.2M in research and development during fiscal year 2025.

How many shares does aTyr Pharma, Inc. have outstanding?

aTyr Pharma, Inc. (ATYR) had 98M shares outstanding as of fiscal year 2025.

What is aTyr Pharma, Inc.'s current ratio?

aTyr Pharma, Inc. (ATYR) had a current ratio of 5.30 as of fiscal year 2025, which is generally considered healthy.

What is aTyr Pharma, Inc.'s debt-to-equity ratio?

aTyr Pharma, Inc. (ATYR) had a debt-to-equity ratio of 0.38 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is aTyr Pharma, Inc.'s return on assets (ROA)?

aTyr Pharma, Inc. (ATYR) had a return on assets of -79.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is aTyr Pharma, Inc.'s P/E ratio?

aTyr Pharma, Inc. (ATYR) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $21.1M as of Oct 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is aTyr Pharma, Inc.'s price-to-sales ratio?

aTyr Pharma, Inc. (ATYR) trades at 111x sales, its market capitalization divided by revenue of $190K revenue, FY2025. The market capitalization is $21.1M as of Oct 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does aTyr Pharma, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, aTyr Pharma, Inc. (ATYR) held $78.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $62.0M over that year. Dividing the one by the other, the reported balance equals about 15 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is aTyr Pharma, Inc.'s Altman Z-Score?

aTyr Pharma, Inc. (ATYR) has an Altman Z-Score of -10.54, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is aTyr Pharma, Inc.'s Piotroski F-Score?

aTyr Pharma, Inc. (ATYR) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are aTyr Pharma, Inc.'s earnings high quality?

aTyr Pharma, Inc. (ATYR) reported a net loss of $74.1M while operations used $62.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.